Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 2,643.98 | 2,440.69 | 2,184.11 | 1,950.48 | 2,088.06 |
Total Expenses | 2,760.10 | 2,447.13 | 2,173.72 | 1,993.23 | 1,890.86 |
Profit Before Tax | -122.26 | -54.59 | -4.25 | -65.03 | 197.20 |
Profit After Tax | -153.45 | -29.80 | 18.01 | -165.13 | 158.51 |
Operating Profit after Depreciation | 3.85 | 79.25 | 67.20 | 4.86 | 259.15 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 6,864.99 | 6,230.15 | 5,792.83 | 5,754.48 | 5,704.68 |
Total Non Current Assets | 7,653.22 | 7,535.14 | 6,798.73 | 6,661.96 | 6,420.84 |
Total Current Assets | 1,928.19 | 1,918.36 | 1,838.72 | 1,704.14 | 1,778.97 |
TOTAL ASSETS | 9,581.41 | 9,453.50 | 8,637.45 | 8,366.10 | 8,199.81 |
Total Shareholder's Fund | 5,627.50 | 5,809.67 | 5,548.94 | 5,698.82 | 5,715.06 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 383.97 | 265.96 | 354.85 | 512.66 | 585.14 |
Net Cash used in Investing Activities | -229.52 | -494.08 | -618.53 | -380.02 | -441.74 |
Net Cash used in Financing Activities | -22.15 | 249.67 | 130.38 | -11.04 | -97.78 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 390.40 | 454.71 | 367 | 266.47 | 650.29 |
Total Expenses | 490.35 | 548.91 | 444.40 | 428.49 | 594.83 |
Profit Before Tax | -103 | -96.20 | -83.31 | -162.02 | 55.46 |
Profit After Tax | -76.41 | -58.87 | -30.47 | -226.14 | 38.52 |
Operating Profit after Depreciation | -31.76 | -36.28 | -40.17 | -127.85 | 102.48 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 1,416.33 | 1,383.31 | 1,359.63 | 1,551.49 | 1,664.24 |
Total Non Current Assets | 4,489.44 | 4,531.43 | 4,448.52 | 4,828.69 | 4,969.99 |
Total Current Assets | 587.22 | 649.61 | 765.79 | 723.06 | 764.69 |
TOTAL ASSETS | 5,076.66 | 5,181.04 | 5,214.31 | 5,551.75 | 5,734.68 |
Total Shareholder's Fund | 4,052.58 | 4,114.31 | 4,231.78 | 4,674.62 | 4,795.85 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 24.17 | -52.90 | 227.35 | -1.51 | 196.70 |
Net Cash used in Investing Activities | 96.57 | 40.71 | -172.67 | 62.07 | -74.30 |
Net Cash used in Financing Activities | -130.76 | 1.38 | -46.16 | -70.53 | -124.07 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 789.04 | 523.78 | 654.71 | 651.09 | 586.59 |
Total Expenses | 641.89 | 494.81 | 592.03 | 609.98 | 525.74 |
Profit Before Tax | 42.12 | -77.56 | -49.20 | -66.29 | -36.26 |
Profit After Tax | 33.09 | -77.57 | -69.92 | -59.63 | -40.90 |
Operating Profit after Depreciation | 153.80 | 30.40 | 69.84 | 47.16 | 69.32 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 93.29 | 103.41 | 111.26 | 86.82 | 59.72 |
Total Expenses | 79.89 | 88.51 | 99.69 | 83.65 | 62.64 |
Profit Before Tax | 5.44 | -5.56 | -33.63 | -27.08 | -9.26 |
Profit After Tax | 14.25 | -3.47 | -31.12 | -18.18 | -5.78 |
Operating Profit after Depreciation | 37.33 | 26.49 | 8.36 | 16.28 | 35.79 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Dishman Carbogen Amcis Ltd | ₹229.20 | ₹3,593.47 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
10 Jan 2025, 03:36 pm
11 Nov 2024, 01:04 pm
30 Aug 2024, 04:52 pm
14 Aug 2024, 03:47 pm
14 Aug 2024, 03:00 pm